Latest news from ProtonDx
• Grant to develop automated, rapid point-of-need diagnostic to provide a sustainable and resilient revolution in detection and diagnosis of Porcine Respiratory Disease Complex (PRDC) • Working in collaboration with Imperial College, farmers and industry experts to help address the global issue of rising antibiotic resistance
Opinion article: Dr Jesus Rodriguez-Manzano, Co-Founder and Chief Scientific Officer (CSO) at ProtonDx, shares his thoughts on anti-microbial resistance (AMR). He discusses what we can learn from the recent COVID‑19 pandemic, including the important role that point-of-need diagnostics can play.
5-in-1 Respiratory Test Panel from ProtonDx used to assess elite athletes at the 2022 Commonwealth Games
Dragonfly™ detects SARS-CoV-2, Flu A, Flu B, RSV and human rhinovirus without a lab. It is a cost-effective point-of-need portable diagnostic system for infectious disease now commercially available.
Lacewing, the futuristic lab-on-a-chip, diagnostic tool is one of eight initiatives promoted by Imperial College London to mark Malaria Day, 25 April, in order to demonstrate the College’s deep commitment to conquering malaria. Lacewing is being developed for health care applications by Imperial spin out company ProtonDx based at the College’s Translation and Innovation HUB (I-HUB), White City Campus.
The Dragonﬂy Respiratory Diagnostic Panel was utilised by the Team GB clinical staﬀ with great success to test Great Britain's athletes at the 2022 Olympic Winter Games in Beijing.
People infected by Covid-19 and influenza face four times the risk of requiring a ventilator and twice the risk of death. Diagnosis of which respiratory viruses are infecting the patient is crucial especially as there is no increased risk of severe illness for those with both Covid-19 and RSV or other respiratory viruses.
Research by Imperial College London suggests that lateral flow tests miss a substantial number of COVID-19 infections, particularly for people without symptoms emphasising the need for rapid, sensitive, accurate and portable tests.
“Better, faster diagnostics will be central to tackling Antimicrobial Resistance in the future,” said ProtonDx Founder & Director, Asst Professor Jesus Rodriguez-Manzano, at a recent FORUM event organised by the Academy of Medical Sciences
ProtonDx CEO, Professor Pantelis Georgiou has won an award for his inspirational work from his colleagues in the Department of Electrical and Electronic Engineering, Imperial College London
ProtonDx is privileged to have secured office space in the prestigious Translation and Innovation Hub (IHUB) at White City campus of Imperial College London.
The work of the ProtonDx team has been recognized in Best of British a government publication produced jointly with Malaria NO MORE.
CEO of ProtonDx, Dr Pantelis Georgiou, was promoted to Professor of Biomedical Electronics in the annual promotion round at Imperial College London, one of only six to achieve this accolade this year.